BACKGROUND: In April 2010, the Department of Health introduced the hip fracture best practice. Among the clinical criteria required to earn remuneration is surgery within 36 h of admission. However, early surgery may mean that methicillin-resistant Staphylococcus aureus (MRSA) colonisation status is not known before surgery, and therefore, appropriate antibiotic prophylaxis may not be administered. In view of this, our department's policy is to administer an additional dose of teicoplanin to patients with unknown MRSA status along with routine antimicrobial prophylaxis. AIM: The purpose of this study was to provide a safe and effective antimicrobial prophylaxis for hip fracture patients. METHODS: We prospectively collected details of demographics and antimicrobial prophylaxis for all patients admitted with a hip fracture in November 2011. This was repeated in February 2012 after an educational and advertising drive to improve compliance with departmental antimicrobial policy. Microbiology results were obtained from the hospital microbiology database. A cost-benefit analysis was undertaken to assess this regime. RESULTS: A total of 144 hip fracture patients were admitted during the 2 months. The average admission to surgery time was 32 h, and the average MRSA swab processing time was 35 h. 86 % of patients reached theatre with unknown MRSA status. Compliance with the departmental antimicrobial policy improved from 25 % in November 2011 to 76 % in February 2012. Potential savings of £ 40,000 were calculated. CONCLUSION: With best practice tariff resulting in 86 % of patients reaching theatre with unknown MRSA status, we advocate an additional single dose of teicoplanin to cover against possible MRSA colonisation.
BACKGROUND: In April 2010, the Department of Health introduced the hip fracture best practice. Among the clinical criteria required to earn remuneration is surgery within 36 h of admission. However, early surgery may mean that methicillin-resistant Staphylococcus aureus (MRSA) colonisation status is not known before surgery, and therefore, appropriate antibiotic prophylaxis may not be administered. In view of this, our department's policy is to administer an additional dose of teicoplanin to patients with unknown MRSA status along with routine antimicrobial prophylaxis. AIM: The purpose of this study was to provide a safe and effective antimicrobial prophylaxis for hip fracturepatients. METHODS: We prospectively collected details of demographics and antimicrobial prophylaxis for all patients admitted with a hip fracture in November 2011. This was repeated in February 2012 after an educational and advertising drive to improve compliance with departmental antimicrobial policy. Microbiology results were obtained from the hospital microbiology database. A cost-benefit analysis was undertaken to assess this regime. RESULTS: A total of 144 hip fracturepatients were admitted during the 2 months. The average admission to surgery time was 32 h, and the average MRSA swab processing time was 35 h. 86 % of patients reached theatre with unknown MRSA status. Compliance with the departmental antimicrobial policy improved from 25 % in November 2011 to 76 % in February 2012. Potential savings of £ 40,000 were calculated. CONCLUSION: With best practice tariff resulting in 86 % of patients reaching theatre with unknown MRSA status, we advocate an additional single dose of teicoplanin to cover against possible MRSA colonisation.
Authors: James P Southwell-Keely; Robert R Russo; Lyn March; Robert Cumming; Ian Cameron; Alan J M Brnabic Journal: Clin Orthop Relat Res Date: 2004-02 Impact factor: 4.176
Authors: K Z Vardakas; E S Soteriades; S A Chrysanthopoulou; P J Papagelopoulos; M E Falagas Journal: Clin Microbiol Infect Date: 2005-10 Impact factor: 8.067
Authors: Curtis G Gemmell; David I Edwards; Adam P Fraise; F Kate Gould; Geoff L Ridgway; Rod E Warren Journal: J Antimicrob Chemother Date: 2006-02-28 Impact factor: 5.790
Authors: A Soriano; D Popescu; S García; G Bori; J A Martínez; V Balasso; F Marco; M Almela; J Mensa Journal: Eur J Clin Microbiol Infect Dis Date: 2006-01 Impact factor: 3.267
Authors: J C De Lucas-Villarrubia; M Lopez-Franco; J J Granizo; J C De Lucas-Garcia; E Gomez-Barrena Journal: Int Orthop Date: 2003-05-15 Impact factor: 3.075
Authors: Antonio De Vincentis; Astrid Ursula Behr; Giuseppe Bellelli; Marco Bravi; Anna Castaldo; Lucia Galluzzo; Giovanni Iolascon; Stefania Maggi; Emilio Martini; Alberto Momoli; Graziano Onder; Marco Paoletta; Luca Pietrogrande; Mauro Roselli; Mauro Ruggeri; Carmelinda Ruggiero; Fabio Santacaterina; Luigi Tritapepe; Amedeo Zurlo; Raffaele Antonelli Incalzi Journal: Aging Clin Exp Res Date: 2021-07-21 Impact factor: 3.636